Arbutus Biopharma Corporation (ABUS)
| Previous close | 3.2900 |
| Open | 3.2500 |
| Bid | 3.2000 x 2200 |
| Ask | 3.2900 x 1800 |
| Day's range | 3.1900 - 3.3750 |
| 52-week range | 1.0100 - 9.0200 |
| Volume | 963,012 |
| Avg. volume | 2,495,633 |
| Market cap | 321.751M |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.
- Zacks
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
